Study to Assess the Safety, Tolerability and Pharmacokinetics of Brensocatib
Status: Ongoing
Details
INS1007-211 – A single-blind, placebo-controlled, parallel-group study to assess the safety, tolerability and pharmacokinetics of brensocatib administered once daily for 4 weeks in subjects with cystic fibrosis
Sponsor: Insmed
NCT04594369
